Australian TGA adopts ICH M3(R2) Nonclinical Guidance

Posted by cdavenport on Tuesday Nov 9, 2010 Under Drug Safety, ICH

The Australian TGA has adopted the EU Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (ICH M3(R2)bb).  The effective date was November 5, 2010.   The purpose of this document is to recommend international standards for, and promote harmonization of, the nonclinical/preclinical safety studies recommended to support human clinical trials of a given scope and duration as well as marketing authorization for pharmaceuticals.  This guidance should facilitate the timely conduct of clinical trials, reduce the use of animals in accordance with the 3R (reduce/refine/replace) principles, and reduce the use of other drug development resources.

Be Sociable, Share!

Leave a Reply